DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-632/S-008, S-011

Knoll Pharmaceutical Company
Attention: Robert J. Mandetta
Associate Director, Regulatory Affairs
3000 Continental Drive- North
Mount Olive, New Jersey 07828-1234

Dear Mr. Mandetta:

Please refer to your supplemental new drug applications dated April 17, 2000, received April 18, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Meridia (sibutramine hydrochloride monohydrate) Capsules, 5mg, 10mg, and 15mg.

We acknowledge receipt of your submissions dated February 9 and 16, 2001.

These supplemental new drug applications, as amended, provide for the use of Meridia (sibutramine HCl monohydrate) Capsules as follows:

Supplement 008 – An addition to the **CLINICAL STUDIES** section of the labeling of text and two tables containing information for the prescribing physician on blood pressure, heart rate, and heart rate variability.

Supplement 011 – An addition to the **CLINICAL STUDIES** and the **DOSAGE AND ADMINISTRATION** sections of the labeling indicating the maintenance of weight loss over an 18 month period thus extending the use of this drug from 1 year to 2 years..

We have completed the review of these supplemental applications (S-008 and S-011) and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted February 16, 2001, patient package insert submitted February 16, 2001).

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplements NDA 20-632/S-008 and S-011." Approval of these submissions by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We are deferring submission of your pediatric study information until December 31, 2002.We are waiving the pediatric study requirement for this action on this application.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call William C. Koch, R.Ph., Regulatory Project Manager, at (301) 827-6412.

Sincerely,

David G. Orloff, M.D.
Director
Division of Metabolic
and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research